241 related articles for article (PubMed ID: 22398037)
41. Hepatitis B virus reverse transcriptase mutations in treatment Naïve chronic hepatitis B patients.
Singla B; Chakraborti A; Sharma BK; Kapil S; Chawla YK; Arora SK; Das A; Dhiman RK; Duseja A
J Med Virol; 2013 Jul; 85(7):1155-62. PubMed ID: 23918533
[TBL] [Abstract][Full Text] [Related]
42. Occult hepatitis B virus infection and lamivudine-resistant mutations in isolates from renal patients undergoing hemodialysis.
Motta JS; Mello FC; Lago BV; Perez RM; Gomes SA; Figueiredo FF
J Gastroenterol Hepatol; 2010 Jan; 25(1):101-6. PubMed ID: 19817965
[TBL] [Abstract][Full Text] [Related]
43. Characteristics of lamivudine-resistant hepatitis B virus (HBV) strains with and without breakthrough hepatitis in patients with chronic hepatitis B evaluated by serial HBV full-genome sequences.
Horiike N; Duong TN; Michitaka K; Joko K; Hiasa Y; Konishi I; Yano M; Onji M
J Med Virol; 2007 Jul; 79(7):911-8. PubMed ID: 17516520
[TBL] [Abstract][Full Text] [Related]
44. rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus.
Liu Y; Xu Z; Wang Y; Li X; Liu L; Chen L; Xin S; Xu D
PLoS One; 2014; 9(2):e89015. PubMed ID: 24586482
[TBL] [Abstract][Full Text] [Related]
45. Antiviral resistance mutations and genotype-associated amino acid substitutions in treatment-naïve hepatitis B virus-infected individuals from the Indian subcontinent.
Ismail AM; Samuel P; Eapen CE; Kannangai R; Abraham P
Intervirology; 2012; 55(1):36-44. PubMed ID: 21311172
[TBL] [Abstract][Full Text] [Related]
46. Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance.
Li MW; Hou W; Wo JE; Liu KZ
J Zhejiang Univ Sci B; 2005 Jul; 6(7):664-7. PubMed ID: 15973769
[TBL] [Abstract][Full Text] [Related]
47. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
48. Detection of hepatitis B virus variants in HBV monoinfected and HBV/HIV coinfected Iranian patients under lamivudine treatment.
Aghasadeghi MR; Bahramali G; Sadat SM; Farahani A; Mohraz M; Davar Siadat S; Mostafavi E; Memarnejadian A; Ardestani MS; Vahabpour R; Saraji AA; Delbaz SA
Curr HIV Res; 2011 Jun; 9(4):263-9. PubMed ID: 21671883
[TBL] [Abstract][Full Text] [Related]
49. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
Sun J; Wang Z; Ma S; Zeng G; Zhou Z; Luo K; Hou J
J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
[TBL] [Abstract][Full Text] [Related]
50. Successful treatment of an entecavir-resistant hepatitis B virus variant.
Yatsuji H; Hiraga N; Mori N; Hatakeyama T; Tsuge M; Imamura M; Takahashi S; Fujimoto Y; Ochi H; Abe H; Maekawa T; Suzuki F; Kumada H; Chayama K
J Med Virol; 2007 Dec; 79(12):1811-7. PubMed ID: 17935165
[TBL] [Abstract][Full Text] [Related]
51. [The mutation patterns of HBV P gene and genotyping in patients with lanivudine-resistant chronic hepatitis B].
Tang JL; Zhou JK
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Oct; 25(5):342-4. PubMed ID: 22338219
[TBL] [Abstract][Full Text] [Related]
52. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y
Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
[TBL] [Abstract][Full Text] [Related]
53. Detection of hepatitis B virus polymerase variations resistant to lamivudine therapy.
Zhang X; Han Y; Lu Z; Zhang D; Cai Y
Chin Med J (Engl); 2000 May; 113(5):455-7. PubMed ID: 11776105
[TBL] [Abstract][Full Text] [Related]
54. Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues.
Wang F; Wang H; Shen H; Meng C; Weng X; Zhang W
Clin Ther; 2009 Feb; 31(2):360-6. PubMed ID: 19302908
[TBL] [Abstract][Full Text] [Related]
55. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.
Warner N; Locarnini S; Kuiper M; Bartholomeusz A; Ayres A; Yuen L; Shaw T
Antimicrob Agents Chemother; 2007 Jul; 51(7):2285-92. PubMed ID: 17438047
[TBL] [Abstract][Full Text] [Related]
56. Monitoring of genotypic resistance profile in chronic hepatitis B patients receiving nucleos(t)ide analogues in Huzhou, China.
Qian F; Qin J; Li D; Ma Z; Zhang H; Jin F; Wang W
J Infect Dev Ctries; 2016 Sep; 10(9):996-1002. PubMed ID: 27694733
[TBL] [Abstract][Full Text] [Related]
57. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
[TBL] [Abstract][Full Text] [Related]
58. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes.
Svicher V; Gori C; Trignetti M; Visca M; Micheli V; Bernassola M; Salpini R; Gubertini G; Longo R; Niero F; Ceccherini-Silberstein F; De Sanctis GM; Spanò A; Cappiello G; Perno CF
J Hepatol; 2009 Mar; 50(3):461-70. PubMed ID: 19041149
[TBL] [Abstract][Full Text] [Related]
59. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
Matsuda M; Suzuki F; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Satoh J; Kobayashi M; Ikeda K; Miyakawa Y; Kumada H
J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
[TBL] [Abstract][Full Text] [Related]
60. Prevalence, virology and antiviral drugs susceptibility of hepatitis B virus rtN238H polymerase mutation from 1865 Chinese patients with chronic hepatitis B.
Zhong Y; Lv J; Li J; Xing X; Zhu H; Su H; Chen L; Zhou X
Antiviral Res; 2012 Jan; 93(1):185-90. PubMed ID: 22138714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
